[1]
|
Elbasmi, A., Al-Asfour, A., Al-Nesf, Y. and Al-Awadi, A. (2010) Cancer in Kuwait Magnitude of the Problem. GJO, 8, 7-14.
|
|
[2]
|
Azzoli, C.G., Baker, S.J., Temin, S., et al. (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 27, 6251-6266.
http://dx.doi.org/10.1200/JCO.2009.23.5622
|
|
[3]
|
Shigematsu, H., Lin, L., Takahashi, T., et al. (2005) Clinical and Biological Features Associated with Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 97, 339-346.
http://dx.doi.org/10.1093/jnci/dji055
|
|
[4]
|
Shi, Y., Au, J.S., Thongprasert, S., et al. (2014) A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-162. http://dx.doi.org/10.1097/JTO.0000000000000033
|
|
[5]
|
Reily, G.J., Politi, K.A., Miller, V.A. and Pao, W. (2006) Update on Epidermal Growth Factor Receptor Mutation in NSCLC. Clinical Cancer Research, 12, 7232-7241. http://dx.doi.org/10.1158/1078-0432.CCR-06-0658
|
|
[6]
|
Pao, W., Miller, V., Zakowski, M., et al. (2004) EGF Receptor Gene Mutations Are Common in Lung Cancers from “Never Smokers” and Are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. The Proceedings of the National Academy of Sciences of the United States of America, 101, 13306-13311.
http://dx.doi.org/10.1073/pnas.0405220101
|
|
[7]
|
Miller, V.A., Riely, G.J., Zakowski, M.F., et al. (2008) Molecular Characteristics of Broncho-Alvealar and Adenocarcinoma, Broncho-Alveolar Carcinoma Subtype, Predict Response to Erlotinib. Journal of Clinical Oncology, 26, 1472-1478. http://dx.doi.org/10.1200/JCO.2007.13.0062
|
|
[8]
|
Lee, C.K., Brown, C., Gralla, R.J., et al. (2013) Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105, 595-605.
http://dx.doi.org/10.1093/jnci/djt072
|
|
[9]
|
Fukuoka, M., Wu, Y.L., Thongprasert, S., et al. (2011) Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology, 29, 2866-2874.
http://dx.doi.org/10.1200/JCO.2010.33.4235
|
|
[10]
|
Inoue, A., Kobayashi, K., Maemondo, M., et al. (2013) Updated Overall Survival Results from a Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Na?ve Non-Small Cell Lung Cancer with Sensitive EGFR Gene Mutations (NEJ002). Annals of Oncology, 24, 54-59. http://dx.doi.org/10.1093/annonc/mds214
|
|
[11]
|
Maemondo, M., Inoue, A., Kobayashi, K., et al. (2010) Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. The New England Journal of Medicine, 362, 2380-2388.
http://dx.doi.org/10.1056/NEJMoa0909530
|
|
[12]
|
Mitsudomi, T., Morita, S., Yatabe, Y., et al. (2010) Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harboring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial. The Lancet Oncology, 11, 121-128. http://dx.doi.org/10.1016/S1470-2045(09)70364-X
|
|
[13]
|
Zhou, C., Wu, Y.L., Chen, G., et al. (2011) Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open Label, Randomised, Phase 3 Study. The Lancet Oncology, 12, 735-742.
http://dx.doi.org/10.1016/S1470-2045(11)70184-X
|
|
[14]
|
Rosell, R., Carcereny, E., Gervais, R., et al. (2012) Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 13, 239-246.
http://dx.doi.org/10.1016/S1470-2045(11)70393-X
|
|
[15]
|
Sharma, S.V., Bell, D.W., Settleman, J. and Haber, D.A. (2007) Epidermal Growth Factor Mutation in Lung Cancer. Nature Reviews Cancer, 7, 169-181. http://dx.doi.org/10.1038/nrc2088
|
|
[16]
|
Johnson, B., et al. (2013) A Multicenter Effort to Identify Driver Mutations and Employ Targeted Therapy in Patients with Lung Adenocarcinomas: The Lung Cancer Mutation Consortium. JCO, 31, Abstract 8019.
|
|
[17]
|
Ardizzoni, A., Boni, L., Tiseo, M., et al. (2007) Cisplatin versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 99, 847-857. http://dx.doi.org/10.1093/jnci/djk196
|
|
[18]
|
Scagliotti, G.V., Parikh, P., von Pawel, J., et al. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3543-3551. http://dx.doi.org/10.1200/JCO.2007.15.0375
|
|
[19]
|
Syrigos, K.N., Vansteenkiste, J., Parikh, P., von Pawel, J., Manegold, C., Martins, R.G., et al. (2010) Prognostic and Predictive Factors in a Randomized Phase III Trial Comparing Cisplatin-Pemetrexed versus Cisplatin-Gemcitabine in Advanced Non-Small-Cell Lung Cancer. Annals of Oncology, 21, 556-561. http://dx.doi.org/10.1093/annonc/mdp392
|
|